Arrowhead Pharmaceuticals
S&P 400
$82.85
+0.11%
Delayed · cached 15 min
Fair value analysis
Reported earnings per share are negative or zero, so the earnings-based models cannot produce a value.
Financial DNA score 27 / 100
Educational data only. Not a recommendation to buy, sell or hold any security.